Amgen, Servier strike deal to sell, develop heart drugs
This article was originally published in Scrip
Amgen and Servier said they reached an agreement to potentially market each other’s heart drugs and co-develop another experimental drug.
You may also be interested in...
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.